Want to see NL:LKFT full AI Analyst Report?
Top Page
Galapagos
(LKFT)
Select Model
Select Model
Rating:66Neutral
Price Target:
€28.00
▲(14.29% Upside)
Action:Reiterated
Date:08/20/26
The score is primarily driven by a split financial profile: an exceptionally strong, low-debt balance sheet and recently improved profitability are tempered by ongoing negative operating/free cash flow and uneven revenue momentum. Technical indicators are mildly weak (negative MACD; below the 200-day average), while the low P/E provides meaningful valuation support.
Positive Factors
Conservative Balance Sheet
Very low leverage gives Galapagos substantial financial resilience and flexibility to fund research, partnerships, or restructuring without depending heavily on external borrowing.
Negative Factors
Persistent Cash Burn
Negative operating and free cash flow in every reported period means the business is not currently self-funding. Continued cash consumption could reduce financial flexibility despite the strong balance sheet.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage gives Galapagos substantial financial resilience and flexibility to fund research, partnerships, or restructuring without depending heavily on external borrowing.
Read all positive factors
Galapagos (LKFT) vs. iShares MSCI Netherlands ETF (EWN)
Market Cap
€1.57B
Dividend YieldN/A
Average Volume (3M)132.01K
Price to Earnings (P/E)3.5
Beta (1Y)0.67
Revenue Growth259.41%
EPS GrowthN/A
CountryNL
Employees452
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)7.39
Shares Outstanding65,897,070
10 Day Avg. Volume76,560
30 Day Avg. Volume132,014
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.00Price Target Upside-10.20% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-2.98
Revenue Forecast (FY)€24.65M
Galapagos Business Overview & Revenue Model
Company Description
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in der...
How the Company Makes Money
null...
Galapagos Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.04B | 1.11B | 275.65M | 239.72M | 505.28M | 484.85M |
| Gross Profit | 1.02B | 1.03B | 240.79M | 203.74M | 493.20M | 483.22M |
| EBITDA | 328.89M | 521.51M | 43.33M | 43.38M | -33.37M | -100.93M |
| Net Income | 488.78M | 320.88M | 74.08M | 211.70M | -217.99M | -125.42M |
Balance Sheet | ||||||
| Total Assets | 3.37B | 3.41B | 4.14B | 4.36B | 4.73B | 5.19B |
| Cash, Cash Equivalents and Short-Term Investments | 2.98B | 3.00B | 3.12B | 3.68B | 4.09B | 4.70B |
| Total Debt | 6.43M | 6.92M | 11.72M | 9.60M | 21.90M | 26.86M |
| Total Liabilities | 119.06M | 170.65M | 1.24B | 1.56B | 2.21B | 2.55B |
| Stockholders Equity | 3.25B | 3.24B | 2.90B | 2.80B | 2.53B | 2.64B |
Cash Flow | ||||||
| Free Cash Flow | -301.12M | -210.71M | -402.14M | -425.24M | -537.49M | -561.71M |
| Operating Cash Flow | -292.39M | -197.01M | -320.03M | -405.97M | -500.54M | -503.83M |
| Investing Cash Flow | 256.36M | 228.37M | 220.60M | 71.19M | -1.25B | 541.24M |
| Financing Cash Flow | -2.77M | -3.27M | -4.92M | -5.00M | -1.49M | -3.88M |
Galapagos Technical Analysis
Positive
24.50
Price Trends
25.02
Positive
24.64
Positive
26.25
Negative
Market Momentum
-0.19
Negative
59.85
Neutral
72.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:LKFT, the sentiment is Positive. The current price of 24.5 is above the 20-day moving average (MA) of 24.03, below the 50-day MA of 25.02, and below the 200-day MA of 26.25, indicating a neutral trend. The MACD of -0.19 indicates Negative momentum. The RSI at 59.85 is Neutral, neither overbought nor oversold. The STOCH value of 72.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NL:LKFT.
Galapagos Peers Comparison
UnderperformOutperform
Sector (55)
NL:LKFT
Galapagos
24.34
-3.04
-11.10%
NL:PHARM
Pharming Group
1.00
-0.10
-8.97%
NL:VVY
Vivoryon Therapeutics AG
1.13
-0.32
-22.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.